Skip to content

Casual picture of a woman smiling, with the text: Nancy Brooks Brody, Sept 12, 1962 – December 8, 2023
Photo with eleven men and women, with the label "TAG History"
Report cover that reads" Pipeline Report 2023. Pipeline report is white text, and 2023 is gray. The main cover is black with a graphic of blue wavy lines

Pipeline Reports

The current ones are all online and available for download now.

February 16, 2024
Research Toward a Cure Trials
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).

February 16, 2024
Effective Approaches to Engaging HIV Positive Homeless Populations
Webinar / Presentation
On February 27, 2024, Join TAG as we explore innovative strategies and successful interventions for addressing the unique challenges faced by people living with HIV who are experiencing homelessness.

February 14, 2024
TAG Announces New Board Leadership
Statement / Press
Treatment Action Group (TAG), the New-York-City-based activist research and policy think tank working to end the epidemics of HIV, TB, and hepatitis C, made leadership changes at its annual Board of Directors meeting on February 10, 2024.

February 7, 2024
TAG Statement on 2024 National Black HIV/AIDS Awareness Day (NBHAAD)
Statement / Press
In the collective effort to engage, educate, and empower advocates around the ongoing impacts on Black communities, and to raise awareness around persistent and new threats to equitably ending the HIV epidemic, this National Black HIV/AIDS Awareness Day beckons us to confront the shadows that linger within our communities, specifically among our Black and Brown queer community members.

January 30, 2024
Health Activist Groups: Defunding UNRWA in Gaza Is an Act of Depravity and Enables a Genocide
Statement / Press
We are appalled. As organisations that have historically worked on issues of health justice and access to medicines for millions of people around the world, for decades, focusing on HIV/AIDS, TB, cancer, and COVID, we share the urgent concern and outrage of aid organizations (NGOs) that the sudden decision by global north donor countries to suspend funding for the United Nations Relief and Works Agency (UNRWA) ‘’comes amid a rapidly worsening humanitarian catastrophe in Gaza.”

January 10, 2024
NOW Is the Time for Hepatitis C Virus Elimination
Hepatitis C-related liver diseases continue to kill an estimated 15,000 people per year in the United States, despite the availability of an effective cure.

December 21, 2023
Hepatitis C Virus Project Consultant
Treatment Action Group (TAG) is seeking a dynamic, highly motivated, and organized Consultant to support the Hepatitis C Virus (HCV) Project in its US domestic work.

December 21, 2023
Statement from TAG, Global TB CAB on H56:IC31 Phase IIb Trial Results
Statement / Press
This week, the Statens Serum Institut (SSI) and IAVI shared topline results of the phase IIb trial of H56:IC31, a subunit TB vaccine developed by SSI in Denmark consisting of four Mycobacterium tuberculosis antigens and the IC31 adjuvant made by Valneva.

December 19, 2023
In Memoriam — Nancy Brooks Brody
September 12, 1962 – December 8, 2023. Treatment Action Group mourns the loss of artist and activist Nancy Brooks Brody, who created the 2021 Limited Art Edition Book Marks for TAG. A native New Yorker, Brody was a member of the artist collective fierce pussy alongside Joy Episalla, Zoe Leonard, and Carrie Yamaoka, from 1991 to 2023. In 2010 fierce pussy created the TAG Limited Art Edition Twisted. We celebrate Brody’s fierce passion, brilliance, and commitment to solidarity and social justice, which lit up our world, through her art and life. TAG extends our condolences to her chosen family, friends, and fierce pussy colleagues.

December 13, 2023
Communities as Actors in the Research and Development Process
This publication explores the role of community engagement in health-related research and development (R&D), particularly within the Unitaid-funded LONGEVITY Project.

December 5, 2023
A Community Update on AbbVie’s HIV Cure Research Program
Webinar / Presentation
This webinar was held on December 5, 2023, and provided an update on HIV cure-related research studies being conducted by the company AbbVie; the recording of the webinar is now online.

December 5, 2023
Report: TB R&D Funding Perilously Off Track of UN Commitments to End Disease by 2030
Statement / Press
A new report released today by Treatment Action Group (TAG) and the Stop TB Partnership has found that cumulative funding for tuberculosis (TB) research and development (R&D) over the past five years is falling shockingly short of commitments.

December 5, 2023
2023 Report on TB Research Funding Trends
TB R&D Report
Tuberculosis Research Funding Trends 2005 – 2022, the 18th annual installment of our series assessing the state of TB R&D, is based on surveys of biomedical research funders conducted by TAG with support from Stop TB Partnership.

November 16, 2023
Submission on the Right to Access and Take Part in Scientific Progress
Letter / Comment
TAG is a longstanding champion of the human right to science, which we believe entitles everyone, everywhere to benefit from the best available tools to end HIV, TB, and HCV.

November 9, 2023
An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis
In 2022, the World Health Organization (WHO) updated its guidelines for treating drug-resistant tuberculosis (DR-TB), recommending a six-month cure. This guide lays out what activists need to know about the new DR-TB treatment regimens, including an overview of findings from the trials that underpin the updated WHO guidelines and important considerations for key populations affected by TB. It is intended to equip advocates with information they need to formulate arguments and push for universal implementation of the best available treatments.  

November 7, 2023
Statement / Press
Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.

November 6, 2023
Treatment Action Group Calls for Immediate Ceasefire in Gaza to Protect Health and Lives
Statement / Press
Treatment Action Group (TAG) urgently calls for an immediate ceasefire in Gaza. We grieve Israeli and Palestinian lives lost before, on, and since October 7, and unequivocally condemn the Hamas attacks that killed more than 1,400 Israelis, including some 30 children.

October 16, 2023
Treatment Action Group Resource on the Demographics of Participation in HIV Cure-Related Clinical Research
In 2014, TAG began tracking HIV cure-related trials and observational studies and making the information available as a listing on our website. The primary sources are online study registries, particularly the US-based

October 6, 2023
TAG Condemns GSK Actions Surrounding Potential TB Vaccine Revealed by Bombshell ProPublica Report
Statement / Press
TAG is appalled by the revelations set forth in Anna Marie Barry-Jester’s deeply reported investigation for ProPublica, “How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits,” published online October 4.

October 4, 2023
TAGline October 2023
We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.

October 2, 2023
TAG Reacts to J&J Commitment to Not Enforce Patents on Bedaquiline
Statement / Press
TAG is thrilled by this weekend’s announcement that following years of activist pressure, Johnson & Johnson (J&J) has finally publicly committed to not enforcing its spurious secondary patents on bedaquiline in the treatment of drug-resistant tuberculosis (DR-TB) in 134 low- and middle-income countries.

September 27, 2023
TAG Remarks Submitted to United Nation High-Level Meetings (UN HLMs), September 2023
TAG prepared these remarks to deliver at United Nations High-Level Meetings (UN HLMs) on tuberculosis (TB), universal health coverage (UHC), and pandemic prevention, preparedness, and response (PPR). While we welcome public reaffirmation of commitments to end TB, we urge member states to take action that goes beyond what’s outlined in the political declarations to stay on track to meet key TB elimination goals.

September 22, 2023
TAG Response to TB Preventive Therapy Price Cut Announcement from USAID and PEPFAR
Statement / Press
TAG welcomes the joint announcement from USAID and PEPFAR at the CDC’s “Prevent TB to End TB” event on the sidelines of the United Nations High-Level Meeting on TB that they have secured a 30% price reduction on the tuberculosis preventive treatment (TPT) regimen called 3HP, taking the price from $14.25 to $9.99 for a three-month patient course.

September 20, 2023
New TAG Analysis: Nearly All Countries “Far Off Track” of Meeting TB Research Targets Despite Publicly Reaffirming Commitments at UN
Statement / Press
As international dignitaries and political leaders gather in New York City this week for the United Nations High-Level Meeting (HLM) on TB, a sobering new analysis from Treatment Action Group (TAG) shows that governments failed to meet previous commitments to fund TB research.

September 19, 2023
At This Week’s UN General Assembly High-Level Meeting on Tuberculosis, the 1/4/6×24 Campaign Calls on Political Leaders to Take Urgent Action for Equitable Access to Shorter, Safer TB Regimens
Statement / Press
Ahead of the United Nations General Assembly High-Level Meeting on the Fight Against Tuberculosis, the 1/4/6×24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

Back To Top